Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
06:19am, Wednesday, 01'st Apr 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel...
Dow Jones and Nasdaq futures flat as Nvidia and Salesforce earnings digested
02:59am, Thursday, 26'th Feb 2026
US stock futures were edging towards a flat start early on Thursday morning, as afterhours earnings from Nvidia and Salesforce continued to be digested....
Nasdaq extends gains as AI takes center stage with Nvidia, Salesforce earnings due
11:22am, Wednesday, 25'th Feb 2026
4:15pm: Big earnings due Tech led the way on Wednesday as investors positioned themselves ahead of a wave of major earnings reports. The Nasdaq jumped 1.3%...
Nasdaq makes strides as Nvidia and Salesforce prepare to report
10:47am, Wednesday, 25'th Feb 2026
3:45pm: Proactive news headlines Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data show its experimental intranasal therapy reduces brain...
Tiziana reports biomarker gains for nasal MS therapy in progressive disease
08:58am, Wednesday, 25'th Feb 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain inflammation and was associated with neuroprote
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
Tiziana reports biomarker gains for nasal MS therapy in progressive disease
03:55am, Wednesday, 25'th Feb 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said new biomarker data from an expanded-access program showed its experimental intranasal therapy reduced brain...
Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison
02:00am, Tuesday, 10'th Feb 2026
Tiziana Life Sciences (NASDAQ: TLSA - Get Free Report) and Tectonic Therapeutic (NASDAQ: TECX - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast
Tiziana Life Sciences publishes positive study on intranasal MS therapy
11:38am, Tuesday, 20'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that a peer-reviewed study of its experimental intranasal therapy for secondary progressive multiple sclerosis (SPMS) has been published in the
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
11:15am, Tuesday, 20'th Jan 2026
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences announces closing of oversubscribed $8.8M offering
03:02pm, Friday, 16'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has closed an $8.8 million equity financing backed by its senior leadership and existing shareholders, as the biotechnology company moves to a
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
02:45pm, Friday, 16'th Jan 2026
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
Tiziana Life Sciences unveils registered direct offering of up to $17.6M
09:00am, Friday, 16'th Jan 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the pricing of a registered direct offering expected to raise up to approximately $17.6 million in gross proceeds, including potential proceeds fr
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
07:00am, Friday, 16'th Jan 2026
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-
